Picoplatin: Difference between revisions
Content deleted Content added
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
{{orphan|date=April 2010}} |
{{orphan|date=April 2010}} |
||
{{ |
{{chembox |
||
| UNII_Ref = {{fdacite|correct|FDA}} |
|||
| UNII = B5TAN0L720 |
|||
| verifiedrevid = 387623931 |
| verifiedrevid = 387623931 |
||
| ImageFile = Picoplatin.png |
| ImageFile = Picoplatin.png |
||
Revision as of 01:37, 1 July 2011
| |
| Names | |
|---|---|
| IUPAC name
azane; 2-methylpyridine; platinum(2+); dichloride
| |
| Identifiers | |
3D model (JSmol)
|
|
| ECHA InfoCard | 100.205.233 |
PubChem CID
|
|
CompTox Dashboard (EPA)
|
|
| |
| Properties | |
| C6H10Cl2N2Pt | |
| Molar mass | 376.14 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
Picoplatin is a cytotoxic platinum compound in clinical development by Poniard Pharmaceuticals (previously NeoRx) for the treatment of patients with solid tumors[1].
In Phase I and Phase II clinical trials, picoplatin demonstrated activity in a variety of solid tumors, including lung, ovarian, colorectal and hormone-refractory prostate cancer.[2] However, in Phase III trials, picoplatin failed to hit its primary endpoint for advanced small cell lung cancer.[3] Hopes are now pinned on its use for metastatic colorectal cancer[4].
References
- ^ The status of platinum anticancer drugs in the clinic and in clinical trials Dalton Transactions
- ^ Picoplatin Clinical Results, Poniard Pharmaceuticals
- ^ Poniard shares crash on Phase III picoplatin failure, fiercebiotech.com, November 16, 2009
- ^ http://www.genengnews.com/specialreports/sritem.aspx?oid=69418732 Nov 2009
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |